WSW, NY, July 30th, 2026, NewsDirect
On July 27, 2026, Entera Bio (NASDAQ: ENTX) shocked the market when it announced an oversubscribed $275 million private placement – a raise that, for a company that started the year at a market capitalization under $60 million, is best described in a word: extraordinary. Just as striking as the size was the investor list. BVF Partners led again, doubling down on a position it originated three months earlier. The new names joining the round read like a directory of the funds that decide which biotech stories the market takes seriously: Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital and Catalio Capital Management.
The fact that the deal came in oversubscribed is not a housekeeping detail. It often means the book was covered several times over – that more capital wanted in than the company was willing to sell – and it tells you what happened to the conversations around Entera in the period before pricing.
The Signal in the Signature
Funds like these do not just ‘swipe right’. The diligence processes at funds like these, who have teams of MDs, PhDs and sometimes support from former FDA reviewers, are some of the most rigorous filters in institutional finance of leading biotechnology companies globally. Weeks or months are spent on scientific and clinical data, endpoint assumptions, statistical plans, commercial and competitive intelligence and regulatory correspondence before a check moves. When funds of this caliber converge on the same conclusion at the same moment on the same asset, the convergence itself is an important signal.
The fact that BVF has led this as the second capital formation event in less than 6 months into Entera is particularly noteworthy. BVF built its thirty-year track record – they’ve invested in firms like ChemoCentryx (Amgen, $3.7B), Blueprint Medicines (Sanofi, $9.5B), Protagonist Therapeutics (J&J talks north of $4B), Kymera, ArQule (Merck, $2.7B) – by finding the potential of these leading biotech giants before the rest of the market did and holding through the middle innings. Their follow-on says the thesis they underwrote in April is testament to their partnership with Entera.
Priced at Market – How Many sub $100 Million Companies Achieve that?
The terms tell you as much as the roster. This was not a discounted round with structured protection. The $275 million was priced at $2.04 per share – one cent below closing Friday July 24 and this was a common stock deal with no warrant coverage. We note that the pre-funded warrants were used only where investors bumped against beneficial-ownership caps. No ratchet, no anti-dilution engineering, no cheap paper. Essentially, an all common stock deal.
Fundamental funds writing checks of this size at market do not do so unless they see significant asymmetric upside relative to the entry price. That is the analytical reality behind the post-deal rally. The market read the terms and the signatures and drew the same conclusion the buyers already had: for these funds, at these check sizes, EB613 is being underwritten as a potential blockbuster drug, and Entera, as a clear leader in oral peptide therapeutics with an extremely promising pipeline across several high value therapeutic areas. And now the perceived financing overhang has been entirely removed so the company is well positioned to execute on its objectives with the support of leading biotech investors.
Entera’s unique position
The setup is uncommon. Entera is not a preclinical story. EB613 is heading into Phase 3 with regulatory guardrails already agreed. In July 2025 the FDA aligned that a single BMD-based Phase 3 could support an NDA. In December 2025 the FDA formally qualified total hip BMD as a validated surrogate for the entire osteoporosis category – the first endpoint ever cleared through the agency’s Biomarker Qualification Program. On June 22, 2026, the FDA gave positive feedback on Entera’s streamlined 750-patient, 12-month Phase 3 protocol. That is the regulatory de-risking many companies never receive before Phase 3 initiation.
The drug itself is derisked and what the population needs. EB613 delivers PTH(1-34), the identical peptide to Eli Lilly’s Forteo – a molecule with more than twenty years of clinical experience. The 161-patient Phase 2 met its primary and secondary endpoints and was published in the Journal of Bone and Mineral Research. At ENDO 2026, Entera showed its Next-Gen single tablet – the commercial formulation heading into Phase 3 – produced a PK/PD profile comparable to both the Phase 2 multi-tablet regimen and to injectable Forteo. No incremental formulation changes are needed for commercialization of EB613. And after this raise, runway now extends into 2030, covering pivotal readout and NDA submission.
And Then There Is the Market
Forteo, at its peak, brought in around $1.7 billion a year as an anabolic injection that fewer than 10% of high-risk patients ever received. That might be the ceiling of a drug delivered by needle. EB613 is positioned to potentially change both the format and expand prescriber and potential patient base. Roughly 200 million women globally live with osteoporosis. In the United States alone, ten million have the disease and forty-four million more have low bone mass. Most are diagnosed by a gynecologist at menopause – and gynecologists do not, in practice, prescribe injectable anabolics. Only 12% do today. In Entera’s own KOL survey, 92% said they would prescribe an oral one.
So, the market is not the current anabolic slice, which itself is measured in the billions. It is potentially much larger, including many of early-stage osteoporosis patients currently getting just an antiresorptive pill like a bisphosphonate – or nothing at all – because the diagnosing physician doesn’t reach for the needle. EB613 would arrive as the first and only oral anabolic in a category with no oral competitor: one pill, once a day, actively rebuilding bone.
Everyone knows someone with osteoporosis. whether that is a grandparent, spouse, a friend or a loved one. This is likely one of the most undertreated chronic progressive disorders which needs an immediate solution. EB613 is poised to help close that gap.
Read this Next >>
Beyond the Dual Agonist: What Retatrutide’s Phase 3 Data Mean for the Future of Obesity Medicine
Recent News Highlights from Entera (NASDAQ: ENTX)
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from Entera Bio Ltd. (the “Issuer”) for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer’s products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer’s public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.
Contact
Wall Street Wire
[email protected]